A number of monoclonal antibody therapies targeting IgE (such as omalizumab) or eosinophilic inflammation (such as mepolizumab, an anti‐IL5 monoclonal antibody) have been developed for severe asthma but have utility in ABPA.66 The gene discussed is IGHE; the disease is asthma.